colchicine/infarkt

Link salvestatakse lõikelauale

Artiklid Kliinilistes uuringutesPatendid

Valige sortimise tüüp

Leht 1 alates 99 tulemused

Differential Effects of Colchicine on Cardiac Cell Viability in an in vitro Model Simulating Myocardial Infarction.

Ainult registreeritud kasutajad saavad artikleid tõlkida

Logi sisse

OBJECTIVE We aimed to examine the effects of colchicine, currently in clinical trials for acute myocardial infarction (AMI), on the viability of cardiac cells using a cell line model of AMI. METHODS HL-1, a murine cardiomyocyte cell line, and H9C2, a rat cardiomyoblast cell line, were incubated with

[Colchicine treatment of recurrent steroid-dependent pericarditis in a patient with post-myocardial-infarction syndrome (Dressler's syndrome)].

Ainult registreeritud kasutajad saavad artikleid tõlkida

Logi sisse

The usual treatment of pericarditis consists of non-steroid anti-inflammatory agents. In cases where the symptoms and/or the pericardial effusion persist or progress, the disease can be arrested in the majority of cases by employing steroids. In some patients, it may prove difficult to conclude

Colchicine and myocardial infarction: A review

Ainult registreeritud kasutajad saavad artikleid tõlkida

Logi sisse

The inflammatory response is frequent after acute myocardial infarction, and may worsen ischaemia-reperfusion injuries, leading to increased infarct size and poor prognosis. Therefore, inflammation may be a promising therapeutic target, and anti-inflammatory drugs appear to be potential additional

Cost-Effectiveness of Low-Dose Colchicine after Myocardial Infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT).

Ainult registreeritud kasutajad saavad artikleid tõlkida

Logi sisse

In the randomized, placebo-controlled Colchicine Cardiovascular Outcomes Trial (COLCOT) of 4745 patients enrolled within 30 days after myocardial infarction, low-dose colchicine (0.5 mg once daily) reduced the incidence of the primary composite endpoint of cardiovascular death,

Colchicine Improves Survival, Left Ventricular Remodeling, and Chronic Cardiac Function After Acute Myocardial Infarction.

Ainult registreeritud kasutajad saavad artikleid tõlkida

Logi sisse

BACKGROUND Several studies have reported that colchicine attenuated the infarct size and inflammation in acute myocardial infarction (MI). However, the sustained benefit of colchicine administration on survival and cardiac function after MI is unknown. It was hypothesized that the short-term

Interest of colchicine in the treatment of acute myocardial infarct responsible for heart failure in a mouse model.

Ainult registreeritud kasutajad saavad artikleid tõlkida

Logi sisse

BACKGROUND Inflammation is deeply involved in the pathophysiology of ischemia-reperfusion (I/R) lesions and ventricular remodeling due to an acute myocardial infarction (AMI). Colchicine as a pleiotropic anti-inflammatory molecule may exert cardioprotective effects under acute ischemia. Here, we

Effect of colchicine on circulating and myocardial neutrophils and on infarct size in a canine model of ischemia and reperfusion.

Ainult registreeritud kasutajad saavad artikleid tõlkida

Logi sisse

Myocardial injury after ischemia/reperfusion has been attributed in part to the effects of neutrophils. We examined whether colchicine, a potent and rapid inhibitor of neutrophils, may reduce inflammatory leukocytosis, prevent postischemic myocardial neutrophil accumulation, and reduce infarct size

Cardioprotective Role of Colchicine Against Inflammatory Injury in a Rat Model of Acute Myocardial Infarction.

Ainult registreeritud kasutajad saavad artikleid tõlkida

Logi sisse

BACKGROUND Inflammation plays a crucial role in the pathophysiology of myocardial ischemia/reperfusion (I/R) injury. A clinical trial has recently reported a smaller infarct size in a cohort of patients with ST-segment elevation myocardial infarction (MI) treated with a short colchicine course. The

Time-to-treatment initiation of colchicine and cardiovascular outcomes after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT)

Ainult registreeritud kasutajad saavad artikleid tõlkida

Logi sisse

Aims: The COLchicine Cardiovascular Outcomes Trial (COLCOT) demonstrated the benefits of targeting inflammation after myocardial infarction (MI). We aimed to determine whether time-to-treatment initiation (TTI) influences the beneficial

An injectable thermosensitive hydrogel loaded with an ancient natural drug colchicine for myocardial repair after infarction.

Ainult registreeritud kasutajad saavad artikleid tõlkida

Logi sisse

Localized administration of anti-inflammatory agents benefits patients after myocardial infarction (MI) by repressing/modulating inflammatory response of the MI region and thus accelerating repair of the impaired tissues. Colchicine (Col), an ancient natural drug, has excellent anti-inflammatory

Colchicine use is associated with decreased prevalence of myocardial infarction in patients with gout.

Ainult registreeritud kasutajad saavad artikleid tõlkida

Logi sisse

OBJECTIVE The ability of antiinflammatory strategies to alter cardiovascular risk has not been rigorously examined. Colchicine is an antiinflammatory agent that affects macrophages, neutrophils, and endothelial cells, all of which are implicated in the pathogenesis of cardiovascular disease. We

COLIN trial: Value of colchicine in the treatment of patients with acute myocardial infarction and inflammatory response.

Ainult registreeritud kasutajad saavad artikleid tõlkida

Logi sisse

BACKGROUND Inflammation is involved during acute myocardial infarction, and could be an interesting target to prevent ischaemia-reperfusion injuries. Colchicine, known for its pleiotropic anti-inflammatory effects, could decrease systemic inflammation in this context. OBJECTIVE To evaluate the

The Low Dose Colchicine after Myocardial Infarction (LoDoCo-MI) study: A pilot randomized placebo controlled trial of colchicine following acute myocardial infarction.

Ainult registreeritud kasutajad saavad artikleid tõlkida

Logi sisse

Following an acute myocardial infarction (MI), patients with persistently elevated biomarkers of inflammation, in particular C-reactive protein (CRP), are at significantly increased risk of further cardiovascular events. Colchicine is a unique anti-inflammatory medication that has

Anti-Inflammatory Treatment With Colchicine in Acute Myocardial Infarction: A Pilot Study.

Ainult registreeritud kasutajad saavad artikleid tõlkida

Logi sisse

BACKGROUND Inflammatory processes have been identified as key mediators of the deleterious effects of ischemia/reperfusion in ST-segment-elevation myocardial infarction. Colchicine is a substance with potent anti-inflammatory properties, suitable for safe use in patients with cardiovascular disease.

Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction.

Ainult registreeritud kasutajad saavad artikleid tõlkida

Logi sisse

Experimental and clinical evidence support the role of inflammation in atherosclerosis and its complications. Colchicine is an orally administered, potent antiinflammatory medication that is indicated for the treatment of gout and pericarditis.We performed

Eelmine
1
2
3
4
5
6
7
Järgmine

Liitu meie
facebooki lehega

Herbal & Natural Medicine

Kõige täiuslikum ravimtaimede andmebaas, mida toetab teadus

Töötab 55 keeles
Taimsed ravimid, mida toetab teadus
Maitsetaimede äratundmine pildi järgi
Interaktiivne GPS-kaart - märgistage ürdid asukohas (varsti)
Lugege oma otsinguga seotud teaduspublikatsioone
Otsige ravimtaimi nende mõju järgi
Korraldage oma huvisid ja hoidke end kursis uudisteuuringute, kliiniliste uuringute ja patentidega

Sisestage sümptom või haigus ja lugege ravimtaimede kohta, mis võivad aidata, tippige ürdi ja vaadake haigusi ja sümptomeid, mille vastu seda kasutatakse.
* Kogu teave põhineb avaldatud teaduslikel uuringutel